Haemonetics Corporation (N:HAE)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 125 Summer Street
BOSTON MA 02110
Tel: 1-781-3569763
Website: https://www.haemonetics.com
IR: See website
<
Key People
Christopher A. Simon
President, Chief Executive Officer, Director
James C. D'arecca
Executive Vice President, Chief Financial Officer
Roy Galvin
President - Global Plasma and Blood Center
Stewart W. Strong
President - Global Hospital
Laurie A. Miller
Chief Human Resource Officer, Senior Vice President
Anila Lingamneni
Executive Vice President, Chief Technology Officer
Michelle L. Basil
Executive Vice President, General Counsel
Josep L. Llorens
Executive Vice President - Global Manufacturing and Supply Chain
 
Business Overview
Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.
Financial Overview
For the 39 weeks ended 30 December 2023, Haemonetics Corporation revenues increased 12% to $965.8M. Net income increased 13% to $97.2M. Revenues reflect Plasma segment increase from $136.6M to $426.9M, Hospital segment increase from $93.9M to $316.7M, Blood Center segment increase from $76.8M to $207.8M, United States segment increase from $224.1M to $724.2M, Europe segment increase from $39.1M to $115.1M, Asia segment increase from $25.5M to $80.7M.
Employees: 3,034 as of Apr 1, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $5,055M as of Dec 30, 2023
Annual revenue (TTM): $1,270M as of Dec 30, 2023
EBITDA (TTM): $334.93M as of Dec 30, 2023
Net annual income (TTM): $126.57M as of Dec 30, 2023
Free cash flow (TTM): $128.75M as of Dec 30, 2023
Net Debt Last Fiscal Year: $676.61M as of Dec 30, 2023
Shares outstanding: 50,786,117 as of Feb 6, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.